List of Excipients in Branded Drug AFTERA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Foundation Consumer Healthcare LLC	AFTERA	levonorgestrel	69536-103	LACTOSE MONOHYDRATE
Foundation Consumer Healthcare LLC	AFTERA	levonorgestrel	69536-103	MAGNESIUM STEARATE
Foundation Consumer Healthcare LLC	AFTERA	levonorgestrel	69536-103	SILICON DIOXIDE
Foundation Consumer Healthcare LLC	AFTERA	levonorgestrel	69536-103	STARCH, CORN

Aftera Excipient Strategy and Commercial Opportunities

Last updated: August 26, 2026

Aftera is a single-dose, over-the-counter emergency contraceptive containing 1.5 mg of levonorgestrel. Its commercial value is driven less by active-ingredient differentiation than by low-cost manufacture, broad retail access, shelf stability, discreet packaging, and consumer usability. The most practical excipient opportunities are lactose-free reformulation, faster disintegration, improved taste, moisture protection, and alternative dosage forms such as orally disintegrating tablets or thin films.

What is Aftera and how is it regulated?

Aftera contains levonorgestrel, a synthetic progestin used for emergency contraception after unprotected intercourse or contraceptive failure. The product is intended for use as soon as possible, generally within 72 hours, although clinical effectiveness declines with time.[1]

Attribute	Aftera profile
Active ingredient	Levonorgestrel
Strength	1.5 mg
Dosage form	Immediate-release oral tablet
Regulatory category	Over-the-counter emergency contraceptive
Primary use	Prevention of pregnancy after unprotected intercourse or contraceptive failure
Prescription requirement	None in the United States
Primary commercial comparators	Plan B One-Step, Take Action, My Choice, Option 2, generic levonorgestrel 1.5 mg products
Main commercial channel	Retail pharmacy, mass merchants, e-commerce, family-planning and institutional channels

The FDA approved nonprescription access to levonorgestrel emergency contraception following the prescription product’s regulatory history and subsequent switch to OTC status.[2] Consumers do not need to provide proof of age or a prescription to purchase levonorgestrel emergency contraception in the United States.

What excipients are used in Aftera?

Aftera’s public product labeling identifies a conventional immediate-release tablet platform. The formulation uses standard pharmaceutical excipients associated with tablet binding, disintegration, lubrication, flow, and release control.[3]

The disclosed inactive-ingredient profile should be verified against the current National Library of Medicine DailyMed record and the package label for the specific marketed product and manufacturer. Levonorgestrel emergency-contraceptive tablets commonly use excipient systems built around:

• Microcrystalline cellulose as a diluent and compression aid.
• Lactose monohydrate as a filler.
• Croscarmellose sodium or sodium starch glycolate as a superdisintegrant.
• Povidone as a binder.
• Magnesium stearate as a lubricant.
• Colloidal silicon dioxide as a glidant.
• Poloxamer or a related surfactant to support wetting and dissolution.

Because levonorgestrel is administered at a low dose, the tablet’s physical properties depend primarily on excipient selection and process control. The active pharmaceutical ingredient represents a small fraction of total tablet mass. This creates room to modify tablet performance without changing the 1.5 mg drug dose.

What does each excipient contribute?

Excipient function	Typical material	Commercial purpose
Dilution and compactibility	Microcrystalline cellulose, lactose	Produces a manufacturable tablet at low drug loading
Disintegration	Croscarmellose sodium, sodium starch glycolate	Supports rapid tablet breakup after ingestion
Binding	Povidone	Improves granule and tablet strength
Lubrication	Magnesium stearate	Prevents sticking and supports tablet ejection
Flow control	Colloidal silicon dioxide	Improves powder handling and die filling
Wetting and dissolution	Poloxamer or similar surfactant	Helps wet the hydrophobic drug and excipient matrix
Coating or taste control	Film-forming polymers and sweeteners	Improves appearance, swallowability, and brand differentiation

The most important formulation risks are low-dose content uniformity, lubricant overuse, delayed disintegration, moisture sensitivity, and variability in dissolution caused by hydrophobic drug particles.

What excipient strategy is most commercially attractive for Aftera?

A low-risk strategy is to preserve the immediate-release tablet while replacing or optimizing excipients that create consumer or procurement disadvantages.

Lactose-free formulation

A lactose-free version could use mannitol, microcrystalline cellulose, dibasic calcium phosphate, or a co-processed excipient system in place of lactose. The opportunity is commercially relevant because lactose intolerance and ingredient avoidance influence consumer purchasing decisions, even when the amount of lactose in a tablet is small.

The principal development issues are:

• Maintaining tablet hardness without slowing disintegration.
• Controlling friability at a smaller tablet size.
• Preserving content uniformity at low levonorgestrel loading.
• Avoiding a chalky mouthfeel in chewable or orally disintegrating products.
• Demonstrating equivalent dissolution and bioavailability.

A lactose-free formulation has a clearer marketing claim than a conventional reformulation, but it is unlikely to create strong patent protection by itself. Protection would depend on a narrowly defined composition, process, or performance profile.

Faster-disintegrating immediate-release tablet

A rapid-disintegration formulation could use a higher-efficiency superdisintegrant, optimized particle size, porous excipients, or direct-compression technology. The commercial claim would be easier to communicate than a conventional excipient change: smaller tablet, faster breakup, or easier administration.

The formulation must avoid implying that faster disintegration produces greater contraceptive efficacy. Levonorgestrel exposure and clinical effectiveness depend on administration timing and absorption, not simply on tablet breakup.

Potential approaches include:

1. Direct compression with microcrystalline cellulose and a high-efficiency superdisintegrant.
2. Mannitol-based orally disintegrating tablets.
3. Co-processed excipients that improve flow and compactibility.
4. Wetting-agent optimization to reduce dissolution variability.
5. Low-force compression to preserve tablet porosity.

Taste-masked orally disintegrating tablet

An orally disintegrating tablet could address users who have difficulty swallowing, lack access to water, or want discreet administration. Mannitol, xylitol, crospovidone, flavor systems, and polymeric taste-masking layers could support this format.

The main technical problem is the bitter or unpleasant taste associated with many active pharmaceutical ingredients. Taste masking can use:

• Drug-resin complexes.
• Polymer coating of levonorgestrel particles.
• Lipid or wax-based microparticles.
• Ionically modified particles, although levonorgestrel’s neutral character limits some ion-exchange options.
• Sweetener and flavor systems combined with rapid swallowing.

A taste-masked product would likely require more development than a standard tablet because the excipients can affect dissolution, uniformity, and bioavailability. Depending on the extent of formulation change, the regulatory pathway could move beyond a simple generic-equivalence strategy.

Thin-film delivery

A sublingual or buccal film could offer discreet administration and eliminate the need to swallow a tablet. It could also support unit-dose packaging and a differentiated consumer experience.

The obstacles are significant:

• Uniform distribution of a low-dose, poorly water-soluble hormone across a thin film.
• Film tack and handling.
• Moisture sensitivity.
• Dose transfer from packaging.
• Taste and mouthfeel.
• Demonstration of comparable systemic exposure.
• Greater packaging and manufacturing complexity.

A film has stronger differentiation potential than a conventional tablet, but its cost of goods and regulatory burden would be higher. The product would probably need a new drug application, a 505(b)(2) application, or another pathway supported by comparative clinical and pharmacokinetic data rather than a routine ANDA approach.

What formulation patents could protect an improved Aftera product?

An excipient strategy can produce intellectual property, but broad protection is difficult because levonorgestrel tablets have been commercially available for years and the excipients are widely used.

The strongest potential claims would usually focus on a combination of measurable features rather than a generic list of excipients.

Formulation claim categories

Claim category	Potential strength	Typical vulnerability
Specific excipient list	Low	Easily challenged as an obvious substitution
Excipient concentration ranges	Low to moderate	Prior-art overlap and routine optimization
Rapid disintegration plus dissolution profile	Moderate	Requires reproducible test data and non-obvious performance
Taste-masked levonorgestrel particles	Moderate to strong	Depends on novelty, process complexity, and data
Moisture-protective tablet and package system	Moderate	May be limited to packaging or process claims
Orally disintegrating dosage form	Moderate	Broad claims face formulation prior art
Thin film with dose-uniformity controls	Moderate to strong	Manufacturing and delivery details can narrow claims
Manufacturing process for low-dose uniformity	Moderate	Process must be difficult to design around
Stability profile under defined conditions	Moderate	Stability claims require robust supporting data

A defensible estate would combine:

• Composition claims.
• Manufacturing-process claims.
• Dissolution or disintegration performance claims.
• Packaging claims.
• Method-of-use claims where permitted.

Method-of-use protection is limited for a standard levonorgestrel emergency-contraception indication because the use is established. A differentiated administration method, such as a validated alternative route or specific patient-use protocol, could support separate claims, but those claims would face substantial validity and enforceability challenges.

What is the Orange Book status of Aftera?

Aftera is an OTC levonorgestrel product, and Orange Book analysis must distinguish the brand’s own regulatory listing from the broader reference-product and generic landscape.

The FDA Orange Book identifies approved drug products, therapeutic equivalence evaluations, patent information where applicable, and exclusivity data.[4] For levonorgestrel emergency contraception, the key commercial fact is that multiple equivalent or substitutable products are already available. That reduces the likelihood that a conventional Aftera tablet has a durable blocking position based solely on the active ingredient.

A product-specific Orange Book conclusion should rely on the current FDA listing for the applicable application number and manufacturer. Public commercial availability alone does not establish that a product has listed patents, unexpired exclusivity, or a standalone patent estate.

When does Aftera lose exclusivity?

Aftera does not appear to depend on a meaningful, long-duration exclusivity period for commercial protection. The levonorgestrel emergency-contraceptive market has multiple OTC products and generic alternatives.

The relevant exclusivity framework is:

Exclusivity type	Commercial relevance to Aftera
New chemical entity exclusivity	Not applicable to levonorgestrel
New clinical investigation exclusivity	Unlikely to be the primary barrier for a standard 1.5 mg product
Orphan exclusivity	Not applicable
Pediatric exclusivity	Not a central commercial protection for this product
Patent exclusivity	Requires product-specific listed patents or enforceable formulation rights
OTC monograph protection	Depends on the applicable FDA regulatory framework and product compliance
Brand differentiation	Remains commercially relevant after legal exclusivity ends

The practical loss-of-exclusivity issue is therefore substitution pressure, not a single cliff date. Retailers and consumers can switch among brands with comparable active ingredients, dosage strengths, and administration instructions.

Which companies are challenging Aftera commercially?

The competitive challenge comes from manufacturers and marketers of levonorgestrel 1.5 mg emergency contraception rather than from a single litigating generic company.

Key competitors include:

• Bayer’s Plan B One-Step, subject to current brand ownership and commercialization arrangements.
• Perrigo-branded or private-label levonorgestrel products.
• Foundation Consumer Healthcare products, depending on the specific brand and market.
• Take Action and other retail emergency-contraception brands.
• Retailer-owned private-label products.
• International levonorgestrel emergency-contraception manufacturers.

The market is price-sensitive. Retailers can change shelf allocation based on wholesale acquisition cost, gross margin, supply reliability, packaging, and consumer recognition. A reformulated Aftera product would need to improve one of those variables rather than rely on a minor excipient change.

What generic entry risks exist for Aftera?

Generic entry risk is high for a conventional levonorgestrel 1.5 mg tablet because:

1. The active ingredient is established.
2. The dosage strength is standardized.
3. The administration route is conventional.
4. Multiple manufacturers have experience with the product category.
5. Substitution is easy for pharmacies and consumers.
6. Excipients are generally available from multiple suppliers.
7. Manufacturing equipment is standard for oral solid dosage products.

The principal barriers are operational rather than patent-based:

• Reliable API sourcing.
• Low-dose blend uniformity.
• Dissolution control.
• Packaging against heat and humidity.
• OTC labeling compliance.
• Retail distribution.
• Inventory management during demand spikes.
• Quality-system maintenance across multiple contract manufacturers.

What could delay a generic launch?

A generic or private-label entrant could face delays from:

• FDA deficiencies concerning bioequivalence or dissolution.
• Inadequate stability data.
• Packaging failures.
• Content-uniformity problems.
• Supplier changes affecting excipient functionality.
• Labeling errors involving timing, vomiting, BMI, or drug interactions.
• Retail qualification and supply-chain requirements.

These risks are manageable and do not create a durable barrier comparable to biologic manufacturing or complex drug-device combination products.

How strong is the patent estate for Aftera?

The patent estate for a standard Aftera tablet is likely weak relative to the commercial importance of the product. The active ingredient and core indication are old, and standard tablet excipients are widely known.

Patent strength would improve if a new product incorporated a technically difficult feature, such as:

• A defined taste-masking architecture.
• A film or orally disintegrating system with demonstrated pharmacokinetic equivalence.
• A moisture-stable low-dose composition.
• A manufacturing process that consistently achieves narrow content-uniformity limits.
• A specialized unit-dose package that materially improves stability.
• A distinct combination product with a separate regulatory rationale.

Even then, the value of the estate would depend on whether competitors could design around the claims using different excipients or manufacturing steps.

What manufacturing and IP barriers matter most?

The highest-value technical barrier is low-dose uniformity. At 1.5 mg per unit, the API must be dispersed consistently through a much larger excipient mass. Direct blending, granulation, ordered mixing, and API particle engineering can each affect content uniformity and dissolution.

Manufacturing priorities

Manufacturing issue	Recommended strategy
Low-dose uniformity	Control API particle size, blend order, mixing energy, and segregation
Poor wetting	Use surfactant or particle-engineering approaches
Slow disintegration	Optimize superdisintegrant type, level, and placement
Tablet sticking	Control lubricant level, tooling, and granule moisture
Moisture sensitivity	Use high-barrier blister or bottle packaging with desiccant where needed
Stability drift	Conduct accelerated and long-term studies under commercial packaging
Supply continuity	Qualify at least two sources for critical excipients
OTC handling	Design for consumer-use errors and clear label comprehension

Excipient suppliers with reliable regulatory documentation can create procurement advantages, but the ingredients themselves generally do not create significant exclusivity. A co-processed excipient or proprietary particle-engineering platform can provide stronger differentiation if it produces measurable performance benefits.

What commercial opportunities exist for an improved Aftera product?

The most credible opportunities are segmented by user need and channel.

Premium consumer product

A premium version could combine:

• Smaller tablet size.
• Lactose-free formulation.
• Faster disintegration.
• Improved packaging.
• Clearer instructions.
• Discreet, tamper-evident unit-dose presentation.

This product could command a higher price only if the formulation benefit is visible and easy to understand.

Institutional and public-health supply

Government agencies, universities, clinics, shelters, and public-health organizations buy on cost, shelf life, packaging, and supply continuity. A robust low-cost formulation with long stability and simple case packaging may have greater commercial value in this channel than a premium dosage form.

E-commerce and telehealth

Online channels reward compact packaging, discreet shipping, subscription replenishment, and reliable fulfillment. A unit-dose blister with strong moisture protection and low shipping volume is commercially attractive.

International markets

International opportunities vary by country because emergency contraception may be sold through pharmacies, clinics, family-planning programs, or general retail. A formulation that tolerates heat and humidity, uses globally available excipients, and has multilingual packaging can support geographic expansion.

Combination and bundled offerings

A package could be commercially differentiated through non-drug components such as:

• Pregnancy-test inclusion.
• Counseling materials.
• Digital access to educational information.
• Multi-unit emergency-contraception packs.

A combination containing another active drug would create additional regulatory, safety, and IP complexity. The commercial case would need to be stronger than for a single-ingredient product.

How does Aftera compare with competing emergency contraceptives?

Product category	Active ingredient	Main advantage	Main limitation	Patent or exclusivity profile
Aftera and levonorgestrel generics	Levonorgestrel 1.5 mg	Low cost, OTC access, familiar tablet	Time-sensitive use and intense price competition	Generally limited for conventional tablets
Plan B One-Step	Levonorgestrel 1.5 mg	Brand recognition	Premium pricing and generic substitution	Brand value exceeds formulation differentiation
Ulipristal acetate products	Ulipristal acetate 30 mg	Different pharmacology and longer labeled window	Prescription requirements may apply in some markets	Separate regulatory and patent analysis
Copper intrauterine device	Copper device	Long-term contraception and emergency use	Requires trained insertion	Device and method-of-use protection differs materially
Next-generation oral products	Varies	Potential extended window or new usability	Development and regulatory cost	Greater opportunity for new composition and method claims

Aftera competes most directly with other levonorgestrel tablets. It competes indirectly with ulipristal acetate and copper intrauterine devices, which address different clinical and logistical needs.

What litigation and settlement issues affect Aftera?

No major, product-defining patent litigation or settlement position should be inferred solely from the Aftera brand name. The relevant legal review must examine:

• The FDA application associated with the marketed product.
• Orange Book patent listings for the relevant reference product.
• Paragraph IV certifications filed by ANDA applicants.
• Federal district court complaints under the Hatch-Waxman framework.
• Any license, supply, or private-label manufacturing agreement.
• Current ownership and commercialization rights.

For a conventional OTC levonorgestrel tablet, litigation risk is more likely to concern regulatory approval, labeling, trade dress, or commercial contracts than a broad composition-of-matter patent. A genuinely differentiated formulation could change that profile, but the claims would need to survive obviousness and design-around analysis.

Key Takeaways

• Aftera is a 1.5 mg levonorgestrel OTC emergency-contraceptive tablet.
• The core formulation is a conventional immediate-release oral solid dosage form.
• The strongest excipient opportunities are lactose-free design, rapid disintegration, taste masking, moisture protection, and low-dose uniformity.
• A standard excipient substitution is unlikely to produce strong patent protection.
• Orally disintegrating tablets and thin films offer more differentiation but require greater regulatory and manufacturing investment.
• Generic entry risk is high because levonorgestrel 1.5 mg tablets are standardized and widely available.
• The commercial moat is more likely to come from cost, retail access, packaging, supply reliability, and consumer usability than from drug-substance patents.
• The highest-value technical issue is consistent low-dose API distribution and dissolution.
• Product-specific Orange Book, patent, litigation, and licensing conclusions require identification of the applicable FDA application and current manufacturer record.

FAQs

Can Aftera be reformulated without changing the levonorgestrel dose?

Yes. A developer can modify excipients, compression conditions, coating, packaging, or dosage form while retaining 1.5 mg of levonorgestrel. The regulatory requirements depend on how materially the change affects dissolution, bioavailability, stability, labeling, and dosage form.

Is a lactose-free Aftera formulation commercially viable?

Yes. A lactose-free tablet could support consumer positioning and institutional procurement. Its commercial value would depend on preserving tablet strength, rapid disintegration, stability, and low manufacturing cost.

Would an orally disintegrating Aftera tablet receive new patent protection?

Possibly, but an ODT label alone is unlikely to be sufficient. Stronger protection would require a novel excipient architecture, taste-masking method, manufacturing process, or defined performance profile that is non-obvious over existing levonorgestrel formulations.

Does levonorgestrel emergency contraception require cold-chain distribution?

No. It is generally distributed as a room-temperature oral solid dosage form. Commercial packaging must still protect the product from heat, humidity, light, and excessive handling during distribution.

What is the most defensible commercial claim for a new Aftera formulation?

The strongest claim is likely to combine an objective formulation benefit with a clear consumer advantage, such as "lactose-free, rapidly disintegrating, moisture-stable tablet." The claim must be supported by validated laboratory data and compliant OTC labeling.

References

1. U.S. Food and Drug Administration. (2022). Plan B One-Step levonorgestrel tablet, 1.5 mg: Prescribing information and consumer labeling. FDA.

2. U.S. Food and Drug Administration. (2013). FDA approves Plan B One-Step emergency contraceptive for OTC use without age or point-of-sale restrictions. FDA.

3. National Library of Medicine. (n.d.). Aftera- levonorgestrel tablet: DailyMed drug label. DailyMed.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.